Equilibrium studies of protein aggregates and homogeneous nucleation in protein formulation

Journal of Pharmaceutical Sciences

Volumn 99, Issue 2, 2010, Pages 632-644

  Kiese, Sylvia ^a   Pappenberger, Astrid ^a   Friess, Wolfgang ^b   Mahler, Hanns Christian ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Denaturation; Dynamic light scattering; Heat stress; IgG; Light obscuration; Mechanical stress; Nucleation; Protein aggregation; Seeding; Shaking; Size exclusion chromatography; Soluble aggregates; Spiking; Turbidity; Visible and subvisible particles

Indexed keywords

IMMUNOGLOBULIN G1; PROTEIN;

ARTICLE; GEL PERMEATION CHROMATOGRAPHY; HEAT STRESS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; OBSERVATIONAL STUDY; PROTEIN AGGREGATION; PROTEIN STRUCTURE; STORAGE; TEMPERATURE; TURBIDITY;

EID: 74049118384     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21858     Document Type: Article

References (32)

1. Branden C, Tooze J. 1998. Introduction to protein structure, 2nd edition. New York: Garland Science. p 410.
2. Rosenberg A. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8:E501-E508.
3. Schellekens H. 2005. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20:vi3-vi9.
4. Patten PA, Schellekens H. 2003. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. Dev Biol (Basel) 112:81-97.
5. Lofgren JA, Wala I, Koren E, Swanson SJ, Jing S. 2006. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J Immunol Methods 308:101-108.
6. Purohit VS, Middaugh CR, Balasubramanian SV. 2006. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J Pharm Sci 95:358-371.
7. Mahler H-C, Friess W, Grauschopf U, Kiese S. 2008. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci Epub ahead of print.
8. Mahler H-C, Muller R, Friess W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 59:407-417.
9. Kiese S, Pappenberger A, Friess W, Mahler H-C. 2008. Shaken, not stirred: Mechanical stress testing of an IgG1 antibody. J Pharm Sci 97:4347-4366.
10. Karshikoff A. 2006. Non-covalent interactions in proteins. 1st edition, London: Imperial College Press. p 348.
11. Carpenter JF, Kendrick BS, Chang BS, Manning MC, Randolph TW. 1999. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol 309:236-255.
12. Wang W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289:1-30.
13. Andrews JM, Weiss WF, Roberts CJ. 2008. Nucleation, growth, and activation energies for seeded and unseeded aggregation of alpha- Chymotrypsinogen A. Biochemistry 47:2397-2403.
14. Chi EY, Weickmann J, Carpenter JF, Manning MC, Randolph TW. 2005. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 94:256-274.
15. Ferrone FA. 1999. Analysis of protein aggregation kinetics. Methods in enzymology. In: Wetzel R, editor. Amyloid, prions, and other protein aggregates, Vol 309. San Diego, CA: Academic Press. pp 256-274.
16. Tyagi AK, Randolph TW, Dong A, Maloney KM, Hitscherich C, Carpenter JF. 2008. IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98:94-104.
17. Kerker M. 1987. Classics and classicists of colloid and interface science: John Tyndall. J Colloid Interface Sci 119:602-604.
18. Ph. Eur. 2008. 2.2.1. Clarity and degree of opalescence of liquids, 6th edition. Brussels, Belgium: European Directorate for the Quality of Medicine (EDQM).
19. Ph. Eur. 2008. 2.9.19. Particulate contamination: Sub-visible particles, 6th edition. Brussels, Belgium: European Directorate for the Quality of Medicine (EDQM).
20. USP. 2009. USP/NF General Chapter <788> Particulate Matter in Injections. Rockville, MD: United States Pharmacopeial Convention.
21. Schule S, Friess W, Bechtold-Peters K, Garidel P. 2007. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations. Eur J Pharm Biopharm 65:1-9.
22. Matheus S, Mahler HC, Friess W. 2006. A critical evaluation of Tm(FTIR) measurements of high-concentration IgG1 antibody formulations as a formulation development tool. Pharm Res 23:1617-1627.
23. WeissWF IV, Hodgdon TK, Kaler EW, Lenhoff AM, Roberts CJ. 2007. Nonnative protein polymers: Structure, morphology, and relation to nucleation and growth. Biophys J 93:4392-4403.
24. Weiss WF, Young TM, Roberts CJ. 2008. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J Pharm Sci 98:1246-1277.
25. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm Res 20:1325-1336.
26. Kendrick BS, Cleland JL, Lam X, Nguyen T, Randolph TW, Manning MC, Carpenter JF. 1998. Aggregation of recombinant human interferon gamma: Kinetics and structural transitions. J Pharm Sci 87:1069-1076.
27. Andrews JM, Roberts CJ. 2007. Non-native aggregation of alpha-Chymotrypsinogen occurs through nucleation and growth with competing nucleus sizes and negative activation energies. Biochemistry 46:7558-7571.
28. Ionescu RM, Vlasak J, Price C, Kirchmeier M. 2007. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97:1414-1426.
29. Mahler HC, Senner F, Mäder K, Mueller R. 2009. Surface activity of a monoclonal antibody. J Pharm Sci in press.
30. Treuheit MJ, Kosky AA, Brems DN. 2002. Inverse relationship of protein concentration and aggregation. Pharm Res 19:511-516.
31. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93:1390-1402.
32. Alford JR, Kendrick BS, Carpenter JF, Randolph TW. 2008. High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. J Pharm Sci 97:3005-3021.